SIREN : 498114115
MED CONSULTING is a French company founded 19 years ago, specialized in the sector Activités des sociétés holding. Based in TOURS (37000), this company of category PME shows in 2024 a revenue of 6.3 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 6 329 802 € | 6 106 516 € | 4 420 450 € | 3 803 453 € | 1 681 917 € | 1 222 438 € | 908 370 € | 637 910 € |
| Net income | 206 136 € | 619 447 € | 408 107 € | 245 969 € | 24 392 € | 950 952 € | 44 228 € | 138 492 € |
| EBITDA | 297 535 € | 843 185 € | 560 183 € | 344 967 € | 84 329 € | 74 355 € | 75 737 € | 210 147 € |
| Net margin | 3.3% | 10.1% | 9.2% | 6.5% | 1.5% | 77.8% | 4.9% | 21.7% |
In 2024, MED CONSULTING achieves revenue of 6.3 M€. Over the period 2016-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +33.2%. Vs 2023: +4%. After deducting consumption (0 €), gross margin stands at 6.3 M€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 298 k€, representing 4.7% of revenue. Warning negative scissor effect: despite revenue change (+4%), EBITDA varies by -65%, reducing margin by 9.1 pts. This reflects costs rising faster than revenue. The operating margin remains fragile, requiring cost vigilance. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 206 k€, i.e. 3.3% of revenue. This profit can be retained or distributed to shareholders.
6 329 802 €
6 329 802 €
297 535 €
294 776 €
206 136 €
4.7%
The debt ratio (= Financial debt / Equity x 100) stands at 13%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 37%. The balance between equity and debt is satisfactory. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 1.1 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 3.3% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment.
13.231%
36.872%
3.3%
1.055
68.0%
In 2024, the debt ratio of MED CONSULTING (13.23) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2024, the financial autonomy of MED CONSULTING (36.9%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2024, the repayment capacity of MED CONSULTING (1.05) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 156.77. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 4.0x. Financial charges are adequately covered by operations.
156.767
3.954
In 2024, the liquidity ratio of MED CONSULTING (156.77) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
In 2024, the interest coverage of MED CONSULTING (4.0x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 90 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 68 days. The company must finance 22 days of gap between collections and payments. Overall, WCR represents 48 days of revenue, i.e. 840 k€ to permanently finance. Over 2016-2024, WCR increased by +1768%, requiring additional financing.
840 155 €
90 j
68 j
0 j
48 j
Based on 54 transactions of similar company sales
in 2024,
the value of MED CONSULTING is estimated at
1 897 649 €
(range 855 731€ - 2 876 811€).
With an EBITDA of 297 535€, the sector multiple of 4.8x is applied.
The price/revenue ratio is 0.59x
(in line with sector norms).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 54 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare MED CONSULTING with other companies in the same sector:
Voir toutes les statistiques du secteur Activités des sociétés holding
The revenue of MED CONSULTING in 2024 is 6.3 M€.
Yes, MED CONSULTING generated a net profit of 206 k€ in 2024.
The headquarters of MED CONSULTING is located in TOURS (37000), in the department Indre-et-Loire.
The tax return of MED CONSULTING is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
MED CONSULTING operates in the sector Activités des sociétés holding (NAF code 64.20Z). See the 'Sector positioning' section above to compare the company with its competitors.